India: Vivimed Labs bags $7.5m additional investment from OrbiMed Asia Ishita Russell January 2, 2018 PremiumPharmaceuticals firm Vivimed Labs has received an additional investment of $7.5 million from healthcare investment firm OrbiMed Asia in its subsidiary Vivimed Labs (Mascarene). Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Should your colleagues be reading this article too? Contact us for corporate subscriptions at firstname.lastname@example.org.